The Long-term Follow-up (LTFU) core supports complete long-term follow-up of all patients receiving blood or marrow transplant (BMT) according to the various protocols of this Program Project.
The specific aims of the LTFU Core are to ensure complete follow-up of all patients undergoing transplantation at the City of Hope, in order to identify detailed information on the incidence and potential risk factors for delayed cardiopulmonary dysfunction, gastrointestinal, renal, reproductive or endocrine dysfunction and subsequent cancers. The Core aims to identify groups at increased risk for the development of these complications, and make recommendations for screening patients identified to be at increased risk. The LTFU Core aims to evaluate patients prospectively in order to describe health-related quality of life (HRQOL) in BMT survivors and collect data on the incidence with risk factors associated with sexual dysfunction, with the aim to assess the impact of physiologic complications on HRQL in this cohort. The LTFU Core members will consist of the Core Director (Dr. Smita Bhatia), Director of Biostatistics (Dr. Joyce Niland), Director of Nursing Research and Education (Dr. Marcia Grant), Director of Endocrinology (Dr. Kandeel), a psychologist (Dr. Rhonda Sherman), a Nurse Coordinator and to Clinical Research Assistants. The Core staff has significant expertise in establishing large cohorts of cancer survivors and addressing survivorship issues. The LTFU Core has developed a customized data-collection instrument and BMT. Mechanisms are currently in place for ensuring annual data collection and data entry for patients undergoing BMT and surviving one or more years. The overall goal of this core is to improve the quality of long term survival of patients undergoing allogeneic or autologous transplantation for leukemia, lymphoma and myelodysplasia, through early identifications of complications, identification of """"""""high risk"""""""" groups, and recommendations for screening and/or interventions for prevention of these adverse outcomes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA030206-19
Application #
6404074
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
1981-07-01
Project End
2005-03-31
Budget Start
Budget End
Support Year
19
Fiscal Year
2000
Total Cost
Indirect Cost
Name
City of Hope National Medical Center
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010
Limaye, Ajit P; La Rosa, Corinna; Longmate, Jeff et al. (2016) Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. Transplantation 100:210-6
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Wang, Xiuli; Wong, ChingLam W; Urak, Ryan et al. (2015) CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clin Cancer Res 21:2993-3002
Mardiros, Armen; Forman, Stephen J; Budde, Lihua E (2015) T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol 22:484-8
Caruso, Hillary G; Hurton, Lenka V; Najjar, Amer et al. (2015) Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res 75:3505-18
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Wussow, Felix; Chiuppesi, Flavia; Martinez, Joy et al. (2014) Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog 10:e1004524
Rushworth, David; Jena, Bipulendu; Olivares, Simon et al. (2014) Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. J Immunother 37:204-13
Jena, Bipulendu; Moyes, Judy S; Huls, Helen et al. (2014) Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep 9:50-6
Singh, Harjeet; Huls, Helen; Kebriaei, Partow et al. (2014) A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257:181-90

Showing the most recent 10 out of 364 publications